Zunveyl is a drug owned by Alpha Cognition Inc. It is protected by 2 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 13, 2042. Details of Zunveyl's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11795176 | Solid forms of Alpha-1062 gluconate |
Jan, 2042
(17 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9763953 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Dec, 2026
(2 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Zunveyl is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Zunveyl's family patents as well as insights into ongoing legal events on those patents.
Zunveyl's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Zunveyl's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 13, 2042 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Zunveyl Generics:
There are no approved generic versions for Zunveyl as of now.
About Zunveyl
Zunveyl is a drug owned by Alpha Cognition Inc. Zunveyl uses Benzgalantamine Gluconate as an active ingredient. Zunveyl was launched by Alpha Cognition in 2024.
Approval Date:
Zunveyl was approved by FDA for market use on 26 July, 2024.
Active Ingredient:
Zunveyl uses Benzgalantamine Gluconate as the active ingredient. Check out other Drugs and Companies using Benzgalantamine Gluconate ingredient
Dosage:
Zunveyl is available in tablet, delayed release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 5MG BASE | TABLET, DELAYED RELEASE | Prescription | ORAL |
| EQ 10MG BASE | TABLET, DELAYED RELEASE | Prescription | ORAL |
| EQ 15MG BASE | TABLET, DELAYED RELEASE | Prescription | ORAL |